Welcome to our dedicated page for Nexalin Tech SEC filings (Ticker: NXL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Nexalin Technology, Inc. filings document a Nasdaq-listed medical technology issuer developing DIFS™ neurostimulation products for mental-health and neurological indications. Its Form 8-K reports cover material agreements for the HALO Clarity pivotal study, Regulation FD clinical-trial updates, Nasdaq listing-compliance notices, equity distribution and at-the-market offering arrangements, and executive employment and equity-compensation matters.
The filing record also documents the company’s common stock and prior warrant securities, including the expiration and delisting of warrants through a Form 25 process. Disclosures identify Nexalin as an emerging growth company and describe governance, capital-structure and corporate-status matters relevant to its public-company reporting.
Nexalin Technology entered a Stock Purchase Agreement with GreenLight Ventures to acquire all 100 outstanding shares of PONM, Inc. for $1.3 million in Nexalin common stock. An initial 45% tranche equaled 959,016 shares issued at closing, with the remaining stock to be issued in three later tranches.
The deal gives Nexalin ownership of PONM’s AI‑integrated digital health platform, which supports its HALO™ Clarity program and Nexalin NeuroCare™ virtual clinic, including infrastructure already deployed at UCSD. A separate Collaboration Agreement engages GreenLight for development and infrastructure services, generally at $10,000 per month over an initial 24‑month term, with Nexalin receiving key software licenses within the PONM field of use.
Nexalin Technology, Inc. reported another quarterly loss while highlighting serious liquidity risk and Nasdaq listing pressure. For the quarter ended March 31, 2026, revenue was only $14,950, down 64% from $41,015 a year earlier, as international equipment sales softened. The company posted a net loss of $2,096,837, slightly worse than the prior-year loss of $1,988,337, and used $1,712,988 of cash in operating activities.
As of March 31, 2026, Nexalin held $1,207,895 in cash and cash equivalents and $1,500,590 in short-term investments, with working capital of $2,481,790. It raised $756,421 of net proceeds by selling 1,395,300 shares through its at-the-market equity program, bringing total ATM gross proceeds to about $1,423,000.
Management states that recurring losses, negative operating cash flow and limited resources create substantial doubt about Nexalin’s ability to continue as a going concern for at least twelve months. The company also received a Nasdaq notice on January 21, 2026 for failing to meet the $1.00 minimum bid price requirement and has until July 20, 2026 to regain compliance. Nexalin continues to advance its Gen-2 SYNC and Gen-3 HALO neurostimulation devices, including signing a roughly $944,820 scope of work with Lindus Health for a pivotal insomnia study.
Nexalin Technology has engaged U.K.-based clinical research group Lindus Health to run its pivotal clinical trial for the HALO™ Clarity device to treat moderate-to-severe insomnia. Under a new Scope of Work, Nexalin will pay approximately $944,820 in direct fees, plus pass-through expenses, with payments tied to milestones.
The randomized, 160-participant, triple-blinded, sham-controlled study is designed to support a planned De Novo submission to the U.S. FDA. Patient enrollment is currently expected to begin in Q2 2026. Nexalin highlights previously published peer-reviewed data showing statistically significant improvements versus sham and positions HALO™ Clarity as a non-invasive, drug-free neurostimulation option within a sleep-tech market estimated at $29.3 billion in 2025.
Nexalin Technology, Inc. files its annual report describing a neurostimulation business still in development and facing significant financial strain. The company recorded a net loss of approximately $8,222,000 for the year ended December 31, 2025, increasing its accumulated deficit to about $92,867,000. Its auditor raises substantial doubt about Nexalin’s ability to continue as a going concern, making future funding critical.
Nexalin is pivoting from its legacy Gen-1 device, which can no longer be newly marketed in the U.S. after a 2019 FDA reclassification, to new 15 milliamp Gen-2 “SYNC” and Gen-3 “HALO” systems. These devices are advancing through FDA Q-Submission and pre-submission processes for indications including anxiety, insomnia, and Alzheimer’s disease, but none yet have U.S. clearance. The company highlights international approvals in China, Oman and Brazil, a China joint venture, and a planned virtual clinic and home-use headset model, all of which remain early-stage and dependent on successful trials and regulatory approvals.
Nexalin Technology, Inc. is advancing plans for a pivotal clinical trial of its HALO™ Clarity device to treat moderate to severe insomnia. The study is intended to support a planned de novo submission to the U.S. Food and Drug Administration for a drug-free insomnia treatment.
The randomized, triple-blinded, sham-controlled trial is designed to enroll at least 150 adults across the United States, using a fully decentralized model through Nexalin’s NeuroCare virtual clinic and electronic data capture system. Lindus Health will collaborate on trial execution, regulatory preparation, and patient recruitment.
This pivotal study builds on previously published 120-patient randomized, double-blind, placebo-controlled data in chronic insomnia that showed clinically meaningful, statistically significant sleep improvements with no significant adverse effects, and on international approvals for Nexalin’s Gen-2 15 mA device for insomnia and related indications.
Nexalin Technology, Inc. received a notice from Nasdaq on January 21, 2026 stating that its common stock no longer meets the minimum $1.00 bid price requirement for continued listing on The Nasdaq Capital Market. This non-compliance is based on the stock’s closing bid price over the last 30 consecutive business days.
The company has 180 calendar days, until July 20, 2026, to regain compliance by having its closing bid price at or above $1.00 per share for at least ten consecutive business days. If it fails to do so, it may qualify for a second 180-day period if it meets other Nasdaq initial listing standards apart from the bid price. If compliance is not regained, Nasdaq may move to delist the stock, although the company could appeal and would expect trading to move to an OTC Markets Group marketplace. Nexalin plans to monitor its stock price and evaluate options to regain compliance.
Nexalin Technology (NXL) filed its Q3 2025 report, highlighting continued operating losses and a going concern warning. Revenue was $18,149 for the quarter, down from $36,031 a year ago, as legacy licensing and equipment sales remained modest. Net loss for Q3 was $2,276,311 versus $2,448,257 in Q3 2024. For the nine months, revenue totaled $129,752 and net loss reached $5,845,635.
Liquidity and capital: Cash and cash equivalents were $590,075 with short‑term investments of $3,762,602, supporting total current assets of $4,817,378 against current liabilities of $357,524. Stockholders’ equity rose to $4,768,416, aided by 2025 equity issuances, including a May/June public offering of 4,090,000 shares with gross proceeds of $5,317,000. The company amended its equity distribution agreement in October to permit ATM sales up to $10,000,000; as of October 15, $4,273,859 remained available under baby shelf limits and 157,000 shares had been sold.
Operations and R&D: Operating expenses were $2,359,832 in Q3, driven by SG&A, salaries, and stock‑based compensation. The company disclosed a substantial accumulated deficit of $90,490,866 and stated there is substantial doubt about its ability to continue as a going concern. On the regulatory front, the FDA accepted a Q‑Submission in October for the Gen‑2 SYNC system targeting Alzheimer’s and dementia, enabling a formal meeting later this year.
Nexalin Technology, Inc. amended its equity distribution agreement with Maxim Group LLC to expand its at-the-market offering capacity. The amendment increases the aggregate offering price from $3,100,000 to up to $10,000,000 under the ATM Program, allowing the company to sell common stock from time to time through the agent.
As of October 15, 2025, approximately $4,273,859 in aggregate amount of shares remained available for sale under the ATM Program. Sales, if any, will be made pursuant to the company’s effective Form S-3 shelf and a new prospectus supplement dated October 15, 2025.
Nexalin Technology filed a prospectus supplement for an at-the-market offering of up to $4,273,859 in gross proceeds of common stock, to be sold from time to time through Maxim Group LLC as sales agent under an existing equity distribution agreement.
The filing relies on Form S-3 General Instruction I.B.6, which caps primary sales at one-third of public float. The company reports an estimated public float of $28,772,576 based on 18,189,606 shares outstanding as of September 30, 2025 (with 2,720,479 held by affiliates) and an October 8, 2025 closing price of $1.86. Nexalin has sold approximately $5,317,000 in the past 12 months under I.B.6, leaving $4,273,859 available under this supplement and the Sales Agreement. Shares trade on Nasdaq as NXL; the last reported price on October 14, 2025 was $1.29 per share.
Nexalin Technology, Inc. (NXL) Form 4 shows Director Leonard Osser (with spouse Marilyn Elson) reported a non-derivative acquisition of 83,333 common shares on 09/29/2025 at a recorded price of $0. After the transaction the reporting parties beneficially own 1,618,577 shares, held directly with shared voting and dispositive power between Mr. Osser and Ms. Elson. The filing is a joint ownership Form 4 and is signed by both reporting persons.